SPARC acquires Bioprojet's rights to investigational medicinal product SCD-044
SPARC and Bioprojet co-owned all SCD-044 related IP, developed through a research collaboration targeting Sphingosine-1-Phosphate Receptors (S1PR) to treat various autoimmune disorders. The acquisition includes full assignment of all patents and patent applications owned or controlled by Bioprojet related to SCD-044.
Under the terms of the agreement, Bioprojet is eligible to receive milestones and royalties on net sales of SCD-044.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content